Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$12.70 USD
+0.85 (7.17%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $12.68 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Income Statements
Fiscal Year end for Olema Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 105 | 107 | 71 | 22 | 4 |
Income After Depreciation & Amortization | -105 | -107 | -71 | -22 | -4 |
Non-Operating Income | 8 | 2 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | -97 | -105 | -71 | -22 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -97 | -105 | -71 | -22 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -97 | -105 | -71 | -22 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -105 | -107 | -71 | -22 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -105 | -107 | -71 | -22 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.25 | 40.00 | 39.52 | 7.02 | NA |
Diluted EPS Before Non-Recurring Items | -2.14 | -2.62 | -1.80 | -3.42 | NA |
Diluted Net EPS (GAAP) | -2.14 | -2.62 | -1.80 | -3.42 | -1.66 |
Fiscal Year end for Olema Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 33.53 | 34.34 | 30.41 | 23.34 | 21.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.53 | -34.34 | -30.41 | -23.34 | -21.60 |
Non-Operating Income | 3.15 | 3.37 | 3.64 | 1.84 | 1.51 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -30.38 | -30.97 | -26.77 | -21.50 | -20.10 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -30.38 | -30.97 | -26.77 | -21.50 | -20.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -30.38 | -30.97 | -26.77 | -21.50 | -20.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 56.28 | 55.57 | 54.78 | 44.98 | 40.72 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 |
Diluted Net EPS (GAAP) | -0.54 | -0.56 | -0.47 | -0.48 | -0.49 |